Product
How long does it take to create an evaluation report?
On average, you will receive the AIRAmed evaluations after only 5 minutes, which allows you to speed up your reporting workflow considerably.
Last update on 2021-12-09 by Cristobal Marin.
Which brain regions are measured?
AIRAscore structure offers automated segmentation into grey matter, white matter, CSF and T1 hypointensities, as well as automated assignment to a variety of anatomical regions. Detailed measurements of all brain lobes, the midbrain and pons, the cerebellum, hippocampus, as well as the ventricular system, allow conclusions to be drawn across the entire spectrum of neurodegenerative diseases.
Last update on 2022-05-11 by Cristobal Marin.
How accurate are the measurements?
For example, the comparability of two measurements of the same patient, measured with the ICC (2.1), is 0.995 for the entire grey matter. AIRAscore structure is thus not only faster, but also better suited to reliably assess a loss of volume than the conventional segmentation tools regularly used in many thousands of scientific studies.
Last update on 2021-12-09 by Cristobal Marin.
Are progression controls possible?
The improved assessment of progression is one of our core goals. Progress controls can be carried out at any time. For comparability of evaluation reports, data sets should be collected from the same scanner and with the same sequence.
Last update on 2021-12-09 by Cristobal Marin.
Which MRI device do I need?
AIRAmed software can process image data from the three major brand manufacturers GE, Phillips and Siemens for clinical field strengths at 1.5 and 3 Tesla.
Last update on 2021-12-09 by Cristobal Marin.
What image data do I need?
The AIRAmed software solutions work with DICOM data sets. A 3D T1 data set is required. Ideally based on an MPRAGE sequence acquired in sagittal slice guidance. The resolution should be about 1 mm in all spatial directions and there should be no visible artefacts in the image.
Last update on 2021-12-09 by Cristobal Marin.
How complex is the technical installation?
The installation including the necessary configurations can be carried out by your IT department or IT service provider in less than one hour.
Last update on 2021-12-09 by Cristobal Marin.
In which countries is the AIRAmed AIRAscore technology available?
AIRAscore has been CE-certified since June, 2020 and approved as a medical device for all European countries and was FDA-cleared for the United States as of Spetember, 2023.
For facilities interest in information or to preview the technology, please complete the “Contact” tab or email to info@airamed.de
Last update on 2023-09-13 by Cristobal Marin.
An excerpt of our references
‘Especially in the case of rare neurological diseases, we are often faced with the problem of whether an individual brain scan is already conspicuous or not. AIRAscore provides great help in our daily work.’
Prof. Dr. Ludger Schöls
Neurologist, University Hospital of Tübingen, Germany
‘With AIRAscore structure, I can support my diagnosis and diagnose changes in brain volume that I would only have been able to detect much later with a purely visual assessment. This added value pleases my patients, but also me as a doctor.’
Dr. Sören Danz
Radiologist, Sindelfingen, Germany
‘AIRAscore structure simply works for me as a radiologist. There are no fixed contract periods and I only use the software when it makes sense. AIRAmed has managed to generate an evaluation report that satisfies me both in terms of the precision of the results and compilation of the evaluated parameters.’
Dr. Nicola Meyer
Radiologist, Hamburg, Germany
‘I am pleased that with AIRAscore structure we now have a way to benefit from the latest scientific findings in our private practice. It only takes a few minutes until I have exact measurement values directly in my PACS, which significantly improve my reporting options.’
PD Dr. Hansjörg Rempp
Radiologist, Stuttgart, Germany
‘We now use AIRAscore structure routinely with our inpatients. The findings report gives us the necessary security here in the assessment of dementia-related diseases.’
Prof. Dr. Gerhard Eschweiler
Psychiatrist, University Hospital of Tübingen, Germany